409 related articles for article (PubMed ID: 31464093)
1. FOXC2 expression and epithelial-mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer.
Børretzen A; Gravdal K; Haukaas SA; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2019 Oct; 5(4):272-286. PubMed ID: 31464093
[TBL] [Abstract][Full Text] [Related]
2. The epithelial-mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients.
Børretzen A; Gravdal K; Haukaas SA; Mannelqvist M; Beisland C; Akslen LA; Halvorsen OJ
J Pathol Clin Res; 2021 May; 7(3):253-270. PubMed ID: 33605548
[TBL] [Abstract][Full Text] [Related]
3. Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?
Konac E; Kiliccioglu I; Sogutdelen E; Dikmen AU; Albayrak G; Bilen CY
Exp Biol Med (Maywood); 2017 Dec; 242(18):1795-1801. PubMed ID: 28836852
[TBL] [Abstract][Full Text] [Related]
4. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.
Gravdal K; Halvorsen OJ; Haukaas SA; Akslen LA
Clin Cancer Res; 2007 Dec; 13(23):7003-11. PubMed ID: 18056176
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of epithelial-mesenchymal transition markers in prostate cancer.
Figiel S; Vasseur C; Bruyere F; Rozet F; Maheo K; Fromont G
Hum Pathol; 2017 Mar; 61():26-32. PubMed ID: 27818287
[TBL] [Abstract][Full Text] [Related]
6. High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma.
Shimoda Y; Ubukata Y; Handa T; Yokobori T; Watanabe T; Gantumur D; Hagiwara K; Yamanaka T; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Araki K; Harimoto N; Katayama A; Hikino T; Sano T; Ogata K; Kuwano H; Shirabe K; Oyama T
BMC Cancer; 2018 May; 18(1):597. PubMed ID: 29801468
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression.
Jiang W; Fan H; Qian C; Ding J; Wang Q; Pang X
BMC Cancer; 2016 Jan; 16():16. PubMed ID: 26758745
[TBL] [Abstract][Full Text] [Related]
8. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.
Lim JC; Koh VC; Tan JS; Tan WJ; Thike AA; Tan PH
Breast Cancer Res Treat; 2015 Feb; 150(1):19-29. PubMed ID: 25677742
[TBL] [Abstract][Full Text] [Related]
10. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
[TBL] [Abstract][Full Text] [Related]
12. Epithelial mesenchymal-like transition occurs in a subset of cells in castration resistant prostate cancer bone metastases.
Haider M; Zhang X; Coleman I; Ericson N; True LD; Lam HM; Brown LG; Ketchanji M; Nghiem B; Lakely B; Coleman R; Montgomery B; Lange PH; Roudier M; Higano CS; Bielas JH; Nelson PS; Vessella RL; Morrissey C
Clin Exp Metastasis; 2016 Mar; 33(3):239-48. PubMed ID: 26667932
[TBL] [Abstract][Full Text] [Related]
13. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box protein C2 contributes to invasion and metastasis of extrahepatic cholangiocarcinoma, resulting in a poor prognosis.
Watanabe A; Suzuki H; Yokobori T; Altan B; Kubo N; Araki K; Wada S; Mochida Y; Sasaki S; Kashiwabara K; Hosouchi Y; Kuwano H
Cancer Sci; 2013 Nov; 104(11):1427-32. PubMed ID: 23919841
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
16. A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer.
Castaneda M; Rodriguez L; Oh J; Cagle-White B; Suh H; Abdel Aziz MH; Lee J
Bioorg Med Chem Lett; 2023 Jul; 91():129369. PubMed ID: 37290495
[TBL] [Abstract][Full Text] [Related]
17. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
18. The expression of AGGF1, FOXC2, and E-cadherin in esophageal carcinoma and their clinical significance.
Ma L; Yang R; Gu J; Jiang H; Li H
Medicine (Baltimore); 2020 Sep; 99(37):e22173. PubMed ID: 32925786
[TBL] [Abstract][Full Text] [Related]
19. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
20. FOXC2 expression links epithelial-mesenchymal transition and stem cell properties in breast cancer.
Hollier BG; Tinnirello AA; Werden SJ; Evans KW; Taube JH; Sarkar TR; Sphyris N; Shariati M; Kumar SV; Battula VL; Herschkowitz JI; Guerra R; Chang JT; Miura N; Rosen JM; Mani SA
Cancer Res; 2013 Mar; 73(6):1981-92. PubMed ID: 23378344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
